Skip to main content
NASDAQ:TPTX

Turning Point Therapeutics News Headlines

$70.45
+1.10 (+1.59 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$66.44
$71.35
50-Day Range
$62.93
$94.59
52-Week Range
$54.43
$141.30
Volume314,724 shs
Average Volume382,457 shs
Market Capitalization$3.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23

Headlines

Turning Point Therapeutics (NASDAQ TPTX) News Headlines Today

SourceHeadline
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business OfficerTurning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
benzinga.com - May 17 at 9:02 AM
Zacks: Analysts Anticipate Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Will Post Earnings of -$1.20 Per ShareZacks: Analysts Anticipate Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Will Post Earnings of -$1.20 Per Share
americanbankingnews.com - May 16 at 12:10 AM
Investors Who Bought Turning Point Therapeutics (NASDAQ:TPTX) Shares A Year Ago Are Now Up 19%Investors Who Bought Turning Point Therapeutics (NASDAQ:TPTX) Shares A Year Ago Are Now Up 19%
nasdaq.com - May 11 at 7:56 PM
Wedbush Weighs in on Turning Point Therapeutics, Inc.s Q2 2021 Earnings (NASDAQ:TPTX)Wedbush Weighs in on Turning Point Therapeutics, Inc.'s Q2 2021 Earnings (NASDAQ:TPTX)
americanbankingnews.com - May 10 at 1:16 AM
Heres What Analysts Are Forecasting For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) After Its First-Quarter ResultsHere's What Analysts Are Forecasting For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) After Its First-Quarter Results
finance.yahoo.com - May 8 at 10:03 AM
Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly  Earnings Results, Misses Expectations By $0.15 EPSTurning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results, Misses Expectations By $0.15 EPS
americanbankingnews.com - May 6 at 3:24 PM
Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational UpdatesTurning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates
finance.yahoo.com - May 5 at 5:47 PM
Turning Point Therapeutics to Host First Quarter 2021 Conference CallTurning Point Therapeutics to Host First Quarter 2021 Conference Call
finance.yahoo.com - April 26 at 1:58 PM
Is TPTX Stock A Buy or Sell?Is TPTX Stock A Buy or Sell?
finance.yahoo.com - April 23 at 1:57 PM
Turning Point initiates early-stage TPX-0131 cancer studyTurning Point initiates early-stage TPX-0131 cancer study
seekingalpha.com - April 13 at 7:54 PM
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK InhibitorTurning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
finance.yahoo.com - April 12 at 1:32 PM
Turning Point Therapeutics Announces New Preclinical Data for Three Drug CandidatesTurning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
finance.yahoo.com - April 9 at 9:58 AM
Turning Points RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor SettingsTurning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings
finance.yahoo.com - April 6 at 5:40 PM
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
finance.yahoo.com - April 5 at 7:43 PM
Turning Point Therapeutics Announces Board ChangesTurning Point Therapeutics Announces Board Changes
finance.yahoo.com - March 31 at 8:19 PM
RSI Alert: Turning Point Therapeutics (TPTX) Now OversoldRSI Alert: Turning Point Therapeutics (TPTX) Now Oversold
nasdaq.com - March 26 at 6:07 PM
Turning Point Therapeutics (TPTX) Shares Cross Below 200 DMATurning Point Therapeutics (TPTX) Shares Cross Below 200 DMA
nasdaq.com - March 24 at 3:09 PM
Read This Before Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) SharesRead This Before Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares
finance.yahoo.com - March 23 at 1:35 PM
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual MeetingTurning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting
finance.yahoo.com - March 10 at 6:14 PM
Turning Point Therapeutics to Participate in  Upcoming Investor ConferencesTurning Point Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 4 at 1:46 PM
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q4 2020 Results - Earnings Call TranscriptTurning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 3 at 7:42 AM
Turning Point Therapeutics, Inc. 2020 Q4 - Results - Earnings Call PresentationTurning Point Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 1 at 7:09 PM
Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational UpdatesTurning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates
finance.yahoo.com - March 1 at 6:09 PM
Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference CallTurning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call
finance.yahoo.com - February 18 at 11:00 AM
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
finance.yahoo.com - February 12 at 11:59 AM
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology DaysTurning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
markets.businessinsider.com - February 4 at 2:22 PM
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology DaysTurning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
finance.yahoo.com - February 4 at 2:22 PM
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung CancerTurning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
finance.yahoo.com - January 29 at 12:30 PM
Growth Investors: Industry Analysts Just Upgraded Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts By 63%Growth Investors: Industry Analysts Just Upgraded Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts By 63%
finance.yahoo.com - January 22 at 9:07 AM
Investors Who Bought Turning Point Therapeutics (NASDAQ:TPTX) Shares A Year Ago Are Now Up 137%Investors Who Bought Turning Point Therapeutics (NASDAQ:TPTX) Shares A Year Ago Are Now Up 137%
finance.yahoo.com - January 13 at 12:19 PM
Turning Point Therapeutics Announces 2021 Milestone TargetsTurning Point Therapeutics Announces 2021 Milestone Targets
finance.yahoo.com - January 11 at 9:58 AM
Turning Point and Zai Lab Broaden CollaborationTurning Point and Zai Lab Broaden Collaboration
finance.yahoo.com - January 11 at 4:40 AM
Turning Point Therapeutics Reaches Analyst Target PriceTurning Point Therapeutics Reaches Analyst Target Price
nasdaq.com - December 15 at 12:57 PM
Benzingas Top Upgrades, Downgrades For December 8, 2020Benzinga's Top Upgrades, Downgrades For December 8, 2020
finance.yahoo.com - December 8 at 3:15 PM
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase InhibitorTurning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
finance.yahoo.com - December 8 at 10:02 AM
Top 10 Healthcare Stocks for the FutureTop 10 Healthcare Stocks for the Future
finance.yahoo.com - November 29 at 7:48 AM
Turning Point Therapeutics Inc.Turning Point Therapeutics Inc.
wsj.com - November 28 at 9:43 PM
News for Turning Point Therapeutics Inc Registered ShsNews for Turning Point Therapeutics Inc Registered Shs
markets.businessinsider.com - November 18 at 7:47 AM
Turning Point Therapeutics EPS beats by $0.12, beats on revenueTurning Point Therapeutics EPS beats by $0.12, beats on revenue
seekingalpha.com - November 12 at 10:32 PM
Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational UpdatesTurning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates
finance.yahoo.com - November 12 at 5:32 PM
Turning Point Therapeutics to Participate in Jefferies Virtual London Healthcare ConferenceTurning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
finance.yahoo.com - November 10 at 6:59 PM
Were Interested To See How Turning Point Therapeutics (NASDAQ:TPTX) Uses Its Cash Hoard To GrowWe're Interested To See How Turning Point Therapeutics (NASDAQ:TPTX) Uses Its Cash Hoard To Grow
finance.yahoo.com - November 10 at 1:58 PM
Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common StockTurning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
finance.yahoo.com - October 29 at 5:55 PM
Turning Point prices $400M equity offeringTurning Point prices $400M equity offering
seekingalpha.com - October 26 at 11:55 PM
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common StockTurning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 11:55 PM
Turning Point Therapeutics launches equity offeringTurning Point Therapeutics launches equity offering
seekingalpha.com - October 26 at 8:42 AM
Turning Points TPX-0022 shows encouraging action in MET-driven cancersTurning Point's TPX-0022 shows encouraging action in MET-driven cancers
seekingalpha.com - October 26 at 8:42 AM
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR SymposiumTurning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
finance.yahoo.com - October 24 at 1:47 PM
Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual SymposiumTurning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
finance.yahoo.com - October 22 at 9:42 AM
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung CancerTurning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer
finance.yahoo.com - October 21 at 12:50 PM
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.